Lipid peroxide-mediated oxidative rearrangement of the pyrazinone carboxamide core of neutrophil elastase inhibitor AZD9819 in blood plasma samples

Drug Metabolism and Disposition

Volumn 43, Issue 10, 2015, Pages 1441-1449

  Gu, Chungang ^a   Lewis, Richard J ^a,b   Wells, Andrew S ^a   Svensson, Per H ^c,d,e   Hosagrahara, Vinayak P ^a   Johnsson, Eskil ^b   Hallström, Gösta ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d SP TECHNICAL RESEARCH INSTITUTE OF SWEDEN   (Sweden)

^e ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANTIOXIDANT; ASCORBIC ACID; AZD 9819; GLUTATHIONE; LEUKOCYTE ELASTASE INHIBITOR; LIPID HYDROPEROXIDE; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; OXAZOLE DERIVATIVE; OXYGEN; PHOSPHATE BUFFERED SALINE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; PYRAZINE DERIVATIVE;

ACIDIFICATION; ANIMAL CELL; ARTICLE; DRUG BLOOD LEVEL; DRUG OXIDATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TRANSFORMATION; EPOXIDATION; EX VIVO STUDY; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; MOLECULAR MECHANICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOPHILICITY; PH MEASUREMENT; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY; X RAY CRYSTALLOGRAPHY; ANIMAL; BLOOD; CHEMISTRY; FEMALE; OXIDATION REDUCTION REACTION; WISTAR RAT;

AMIDES; ANIMALS; FEMALE; HUMANS; LIPID PEROXIDES; MALE; OXIDATION-REDUCTION; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PYRAZINES; RATS; RATS, WISTAR;

EID: 84946205046     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.065136     Document Type: Article

References (32)

1. Apeloig Y, Karni M, and Rappoport Z (1983) The role of hyperconjugation in determining the stereochemistry of nucleophilic epoxidation and cyclopropanation of electrophilic olefins. J Am Chem Soc 105:2784-2793.
2. Bahar FG, Ohura K, Ogihara T, and Imai T (2012) Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci 101:3979-3988.
3. Battista JR and Marnett LJ (1985) Prostaglandin H synthase-dependent epoxidation of aflatoxin B1. Carcinogenesis 6:1227-1229.
4. Bortolini O, Fantin G, and Fogagnolo M (2009) A simple and efficient oxidation procedure for the synthesis of acid-sensitive epoxides. Synthesis 7:1123-1126.
5. Chen HJ and Chung FL (1996) Epoxidation of trans-4-hydroxy-2-nonenal by fatty acid hydroperoxides and hydrogen peroxide. Chem Res Toxicol 9:306-312.
6. Cutting G, Hansen PR, and Lindsjö M (2011) Preparation of polymorphic forms of cyanophenylpyrazolylmethyloxotrifluoromethylphenyldihydropyrazine carboxylic acid ethylamide derivatives for use as neutrophil elastase inhibitors. US Patent US 20110224229 A1. Assignee: AstraZeneca AB, Sweden; AstraZeneca UK Limited.
7. Erve JCL (2008) Cyclic metabolites: chemical and biological considerations. Curr Drug Metab 9: 175-188.
8. Frei B, England L, and Ames BN (1989) Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 86:6377-6381.
9. Frei B, Stocker R, and Ames BN (1988) Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 85:9748-9752.
10. Gao H, Jacobs A, White RE, Booth BP, and Obach RS (2013) Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests? AAPS J 15:970-973.
11. Girotti AW (1998) Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 39:1529-1542.
12. Guengerich FP (2007) Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol 21:163-168.
13. Iwahashi H, Ikeda A, and Kido R (1985) Haemoglobin-catalysed retinoic acid 5,6-epoxidation. Biochem J 232:459-466.
14. Li W, Zhang J, and Tse FLS (2011) Strategies in quantitative LC-MS/MS analysis of unstable small molecules in biological matrices. Biomed Chromatogr 25:258-277.
15. Lucas SD, Costa E, Guedes RC, and Moreira R (2013) Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase. Med Res Rev 33 (Suppl 1): E73-E101.
16. Ma S and Chowdhury SK (2011) Analytical strategies for assessment of human metabolites in preclinical safety testing. Anal Chem 83:5028-5036.
17. McKillop A and Sanderson WR (2000) Sodium perborate and sodium percarbonate: Further applications in organic synthesis. J Chem Soc, Perkin Trans 1 2000: 471-476.
18. Mitchell SC (2014) Xenobiotic-urea conjugates; chemical or biological? Xenobiotica 44: 1055-1066.
19. Ortiz de Montellano PR (1992) Catalytic sites of hemoprotein peroxidases. Annu Rev Pharmacol Toxicol 32:89-107.
20. Ortiz de Montellano PR and Catalano CE (1985) Epoxidation of styrene by hemoglobin and myoglobin. Transfer of oxidizing equivalents to the protein surface. J Biol Chem 260: 9265-9271.
21. Parkinson A (2001) Biotransformation of xenobiotics, in Casarett and Doull's Toxicology: The Basic Science of Poisons, Ed. 6th (Klaassen CD ed) pp 133-224, McGraw-Hill, New York.
22. Penner N, Xu L, and Prakash C (2012) Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25: 513-531.
23. Pozdnyakova N, Makarov O, Chernyshova M, Turkovskaya O, and Jarosz-Wilkolazka A (2013) Versatile peroxidase of Bjerkandera fumosa: substrate and inhibitor specificity. Enzyme Microb Technol 52:44-53.
24. Reed GA (1987) Co-oxidation of xenobiotics: lipid peroxyl derivatives as mediators of metabolism. Chem Phys Lipids 44:127-148.
25. Rozet E, Marini RD, Ziemons E, Boulanger B, and Hubert P (2011) Advances in validation, risk and uncertainty assessment of bioanalytical methods. J Pharm Biomed Anal 55:848-858.
26. Scheick C and Spiteller G (1993) Bildung von enolether-epoxiden durch einwirkung von (9S,10E,12Z)-hydroperoxyoctadecadiensäure auf plasmalogene. Liebigs Ann Chem 12: 1245-1248.
27. Sharma R, Eng H, Walker GS, Barreiro G, Stepan AF, McClure KF, Wolford A, Bonin PD, Cornelius P, and Kalgutkar AS (2011) Oxidative metabolism of a quinoxaline derivative by xanthine oxidase in rodent plasma. Chem Res Toxicol 24:2207-2216.
28. Singh R, Silva Elipe MV, Pearson PG, Arison BH, Wong BK, White R, Yu X, Burgey CS, Lin JH, and Baillie TA (2003) Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. Chem Res Toxicol 16:198-207.
29. Sjö P (2012) Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors. Future Med Chem 4:651-660.
30. 13C-labels, mass spectrometry, and NMR. Drug Metab Dispos 31: 1437-1447.
31. Tschirret-Guth RA and Ortiz de Montellano PR (1996) Protein radicals in myoglobin dimerization and myoglobin-catalyzed styrene epoxidation. Arch Biochem Biophys 335: 93-101.
32. Zhuo X, Hartz RA, Bronson JJ, Wong H, Ahuja VT, Vrudhula VM, Leet JE, Huang S, Macor JE, and Shu Y-Z (2010) Comparative biotransformation of pyrazinone-containing corticotropin-releasing factor receptor-1 antagonists: minimizing the reactive metabolite formation. Drug Metab Dispos 38:5-15.